TRANSITION: An Observational Study of the Effects on Sweat Chloride and Clinical Outcomes of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)
Phase of Trial: Phase II
Latest Information Update: 14 May 2019
Price : $35 *
At a glance
- Drugs Ivacaftor/tezacaftor (Primary) ; Ivacaftor/lumacaftor
- Indications Cystic fibrosis
- Focus Pharmacodynamics
- Acronyms TRANSITION
- 08 May 2019 Planned End Date changed from 31 Dec 2019 to 1 Mar 2021.
- 08 May 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Mar 2020.
- 31 Aug 2018 Biomarkers information updated